Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading
Metasite, and Linical Americas, a U.S. subsidiary of The Linical
Group, a leading global contract research organization (CRO), today
announced a partnership that will facilitate the deployment of
decentralized clinical trial solutions—powered by Science 37—to
Linical’s international clients, enabling patient access from
virtually anywhere.
As part of the collaboration, Linical will integrate Science
37’s virtual site capabilities into its network, to deliver faster,
more inclusive, patient-centric trials to global research clients.
The partnership will enable decentralized and hybrid trials,
focusing on treatments in the oncology, central nervous system, and
infectious disease therapeutic areas.
“By partnering with Linical, we have an important new ally in
our mission to accelerate clinical research and enable universal
access for patients,” said David Coman, Chief Executive Officer of
Science 37. “Our technology-enabled Metasite will empower and
enhance Linical’s solutions, helping patients access new
life-changing treatments quicker, in the largest and most prevalent
therapeutic areas.”
Linical is a mid-size CRO headquartered in Osaka, Japan, with
offices in multiple locations across North America, Europe, and
Asia. By focusing on three major therapeutic areas—oncology, CNS,
and infectious disease—Linical can deliver “the right size, right
reach, and right team” from early-stage trials to large,
multinational studies.
“We are delighted to become a certified partner with Science 37,
and we look forward to providing our global clients with the
numerous proven benefits of decentralized and hybrid trials enabled
by Science 37,” said Vita Lanoce, MS, Chief Executive Officer of
Linical Americas. “Science 37’s deep expertise and experience in
oncology, CNS, and infectious disease align very much with our own.
We look forward to working with them to help our global clients
accelerate research, enable universal access, and reduce the
patient burden in these important therapeutic areas.”
About Science 37Science 37, Inc.’s (Nasdaq:
SNCE) mission is to accelerate clinical research by enabling
universal access for patients. In 2014, we pioneered decentralized
clinical trials, and we continue to lead, delivering faster, more
inclusive, patient-centric trials, by removing barriers to access
through a tech-enabled virtual site. The Science 37 Metasite™
leverages a unified set of people, processes, and technology,
delivering greater consistency and regulatory-quality data. With
the most medical and operational experience across therapeutic
areas, Science 37 has enabled up to 21x faster enrollment, 28%
better retention, and 3x more diversity vs. the traditional site.
To learn more, visit www.science37.com, or email
science37@science37.com.
About LinicalLinical is a public, mid-sized
Contract Research Organization headquartered in Japan with a
significant presence across North America, Europe, and
Asia-Pacific. Linical provides the full spectrum of drug
development services from early stage to large-scale, multinational
studies. Our areas of focus include Phase I-IV studies in oncology,
infectious disease, and CNS. Rather than be all things to the
market, this intentional design allows us to provide our clients
the right size, right reach, and right team.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains certain
forward-looking statements within the meaning of the federal
securities laws, including statements regarding the products
offered by Science 37, its sales pipeline and the markets in which
it operates. These forward-looking statements generally are
identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result” and similar expressions.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, including but not limited to: (i) the ability to maintain
the listing of Science 37’s securities on Nasdaq, (ii) volatility
in the price of Science 37’s securities due to a variety of
factors, including changes in the competitive and highly regulated
industries in which Science 37 operates, variations in performance
across competitors, changes in laws and regulations affecting
Science 37’s business and changes in its capital structure, (iii)
the ability to implement business plans, forecasts, and other
expectations, and to identify and realize additional opportunities,
(iv) the risk that Science 37 may never achieve or sustain
profitability, (v) the risk that Science 37 will need to raise
additional capital to execute its business plan, which may not be
available on acceptable terms or at all, (vi) failure to realize
anticipated cost savings, and (vii) the potential adverse effects
of the ongoing global COVID-19 pandemic. The foregoing list of
factors is not exhaustive. You should carefully consider the
foregoing factors and the other risks and uncertainties described
in the “Risk Factors” section of our Annual Report on Form 10-K for
the fiscal year ended December 31, 2021 filed with the U.S.
Securities and Exchange Commission (the “SEC”) on March 22, 2022
and in our other documents filed by Science 37 from time to time
with the SEC. These filings identify and address other important
risks and uncertainties that could cause actual events and results
to differ materially from those contained in the forward-looking
statements. Forward-looking statements speak only as of the date
they are made. Readers are cautioned not to put undue reliance on
forward-looking statements, and Science 37 assumes no obligation
and does not intend to update or revise these forward-looking
statements, whether as a result of new information, future events,
or otherwise, except as required by law. Science 37 does not give
any assurance that Science 37 will achieve its expectations.
MEDIA INQUIRIES:Grazia MohrenScience
37PR@science37.com
Alison CundariLinicalacundari@linicalamericas.com
INVESTOR RELATIONS:Steve HalperLifeSci
AdvisorsInvestors@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Sep 2023 to Sep 2024